Description
Diaglizid (gliclazide) tablets 0.08 g. №60
Ingredients
Diaglizid tablets contain 0.08 g of gliclazide as the active ingredient.
Mechanism of Action
Gliclazide, a sulfonylurea, acts by stimulating insulin release from pancreatic beta cells, thereby reducing blood glucose levels in patients with type 2 diabetes mellitus.
Pharmacological Properties
Gliclazide exhibits hypoglycemic effects by binding to specific receptors on pancreatic beta cells, leading to increased insulin secretion and subsequent glucose utilization in peripheral tissues.
Indications for Use
Diaglizid tablets are indicated for the management of type 2 diabetes mellitus to achieve glycemic control and lower blood glucose levels.
Contraindications
Avoid using Diaglizid tablets if you have a history of hypersensitivity to gliclazide, sulfonylureas, or if you have type 1 diabetes.
Side Effects
Common side effects of Diaglizid tablets may include hypoglycemia, gastrointestinal disturbances, skin reactions, and hematological abnormalities. Consult your healthcare provider if you experience any adverse reactions.
Usage Instructions
Take Diaglizid tablets as directed by your healthcare provider. The usual starting dose is 80 mg once daily with breakfast. Swallow the tablet whole with a glass of water.
Benefits Compared to Analogues
Diaglizid tablets offer the advantage of effective glycemic control with a lower risk of cardiovascular events compared to other sulfonylureas, as demonstrated in clinical studies.
Suitable Patient Groups
Diaglizid tablets can be used in adult patients with type 2 diabetes mellitus, including elderly individuals. However, dosing adjustments may be necessary in patients with renal or hepatic impairment.
Storage and Shelf Life
Store Diaglizid tablets in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product beyond the stated shelf life.
Packaging Description
Each package of Diaglizid tablets contains 60 tablets, each with a strength of 0.08 g of gliclazide. The packaging is designed to maintain product integrity and protect the tablets from environmental factors.
Clinical Evidence and Proven Effectiveness
Studies have shown that gliclazide effectively controls blood glucose levels in patients with type 2 diabetes. For instance, a study by Standl et al. (2010) reported a reduced risk of cardiovascular events with gliclazide treatment compared to other sulfonylureas.
